Approaches to target the IL-6/IL-6R signaling pathway have been tested in a cohort of transplant-eligible newly diagnosed MM patients using the anti-IL6 antibody siltuximab in combination with lenalidomide, bortezomib and dexamethasone (Table 1). The gene discussed is IL6; the disease is Miyoshi myopathy.